Intellipharmaceutics International Inc. (NASDAQ:IPCI) Stock Rating Lowered by ValuEngine

Barsaba Taglieri
Agosto 10, 2017

First Foundation Advisors boosted its stake in shares of Intellipharmaceutics International Inc.

ILLEGAL ACTIVITY WARNING: "Zacks Investment Research Lowers Intellipharmaceutics International Inc". The firm now has a buy rating on the stock. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. The firm's 50 day moving average price is $2.26 and its 200-day moving average price is $2.31. The firm's market cap is $37.30 million. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT.

A number of analysts recently commented on IPCI shares. Aegis downgraded shares of Intellipharmaceutics International from a "buy" rating to a "hold" rating and cut their price target for the stock from $8.00 to $2.00 in a report on Wednesday, April 12th.

Shares of Intellipharmaceutics International (IPCI) traded down 12.368% during trading on Friday, hitting $0.999. Zacks Investment Research cut shares of Intellipharmaceutics International from a hold rating to a sell rating in a research report on Friday, July 14th. ValuEngine raised shares of Intellipharmaceutics International from a "sell" rating to a "hold" rating in a report on Friday, May 26th. They now have a United States dollars 2 price target on the stock. Intellipharmaceutics International has a one year low of $1.19 and a one year high of $3.35. "(IPCI) to Sell" was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/10/intellipharmaceutics-international-inc-nasdaqipci-earns-buy-rating-from-maxim-group-updated-updated.html.

An institutional investor recently raised its position in Intellipharmaceutics International stock.

02/24/2015 - Intellipharmaceutics International Inc. had its "equal weight" rating reiterated by analysts at Barclays. (NASDAQ:IPCI) (TSE:I) by 52.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.

TRADEMARK VIOLATION NOTICE: This report was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. The fund owned 274,592 shares of the company's stock after buying an additional 173,692 shares during the period. Institutional investors and hedge funds own 3.86% of the company's stock.

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE